

06-29-2000

Docket No.: MISC.HOSTETLER

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office



101393440

Tab settings

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):
NeXstar Pharmaceuticals, Inc.

Handwritten: 5-23-00

Additional names(s) of conveying party(ies) ☐ Yes ☐ No

3. Nature of conveyance:

- ☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Other

Execution Date: 05/10/00

2. Name and address of receiving party(ies):

Name: Karl Y. Hostetler

Internal Address:

Street Address: 14024 Rue St. Raphael

City: Del Mar State: CA ZIP: 92014

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or registration numbers(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)

07/216,412 07/530,556
07/319,485
07/702,074
07/730,273

B. Patent No.(s)

5,223,263 5,554,728
5,194,654
5,463,092
5,411,947

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Barry J. Swanson

Internal Address:

Street Address: SWANSON & BRATSCHEUN, L.L.C.

1745 Shea Center Drive, Suite 330

City: Highlands Ranch State: CO ZIP: 80126

6. Total number of applications and patents involved: 10

7. Total fee (37 CFR 3.41): \$ 400.00

☒ Enclosed - Any excess or insufficiency should be credited or debited to deposit account

☐ Authorized to be charged to deposit account

8. Deposit account number:

19-5117

06/30/2000 RSL011 00000110 07216412

DO NOT USE THIS SPACE

01 FC:501 400.00 DP

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Margaret M. Wall

Name of Person Signing

Signature

Date

Total number of pages including cover sheet, attachments, and document: 10

PATENT
REEL: 010871 FRAME: 0471

**ASSIGNMENT OF ISSUED PATENTS AND
PENDING PATENT APPLICATIONS**

WHEREAS, Vestar, Inc. ("Vestar"), a corporation that was organized and existed under the laws of the State of Delaware, USA, formerly of 650 Cliffside Drive, San Dimas, California 91773, USA, was merged into and with NeXstar Pharmaceuticals, Inc. ("Assignor"), a corporation organized and existing under the laws of the State of Delaware, USA, of 2860 Wilderness Place, Suite 200, Boulder, CO 80301, USA, by resolution of the Board of Directors of Assignor as evidenced by a Certificate of Ownership and Merger Merging Vestar, Inc. into NeXstar Pharmaceuticals, Inc. effective September 30, 1995, whereby the Assignor acquired the right to alienate intellectual property of Vestar, including the patents and applications ("Patents") in Appendix A;

WHEREAS, Assignor became and remains a wholly owned subsidiary of Gilead Sciences, Inc. ("Gilead"), a corporation organized and existing under the laws of the State of Delaware, USA, of 333 Lakeside Drive, Foster City, California 94404, USA, by an Agreement and Plan of Merger dated February 28, 1999;

WHEREAS, Gilead and Assignor have agreed with Karl Y. Hostetler ("Assignee"), a United States citizen of 14024 Rue St. Raphael, Del Mar, California 92016, USA, that the Patents listed in Appendix A are to be or have been conveyed to Assignee;

NOW THEREFORE, Assignor, for adequate consideration received from Assignee, does hereby sell, assign, and transfer to Assignee all of Assignor's right, title and interest in, to and under each said Patent and all corresponding patents and applications. The Assignor hereby authorizes and requests the United States Commissioner of Patents and Trademarks to issue Letters Patent on U.S. applications listed in Appendix A to said Assignee, for his interest as Assignee, his successors, assigns and legal representatives.

The Assignor hereby agrees to execute such additional papers for Assignee, his successors, assigns and legal representatives, as may be deemed essential by Assignee to perfect his title in all countries in and to the patents and patent applications transferred hereunder.

NEXSTAR PHARMACEUTICALS, INC.

Name: Mark L. Perry *MLP*
Title: Vice President and CFO


State of California)
)
County of San Mateo) SS.

On May 10 2000, before me, Robin Torres, Notary Public, personally appeared Mark L. Perry, personally known to me to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity, and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

Witness my hand and official seal.

Robin Torres

LAWPDOCS\Prodrug.asgt.lt2 wpd mmw



APPENDIX A

TITLE	APPLICATION NO.	PATENT NO.	STATUS	REFERENCE NO.
PROSOME APPLICATIONS/PATENTS				
Phospholipid Derivatives of Dideoxynucleosides and Other Antiviral Nucleosides for Liposomal Incorporation and Method of Use	07/216,412		ABANDONED	VICAL.01A
Phospholipid Derivatives of Dideoxynucleosides and Other Antiviral Nucleosides for Liposomal Incorporation and Method of Use	07/319,485		ABANDONED	VICAL.01B
Phospholipid Derivatives of Dideoxynucleosides and Other Antiviral Nucleosides for Liposomal Incorporation and Method of Use	07/702,074		ABANDONED	VICAL.01C
Liponucleotide-Containing Liposomes	07/373,088	5,223,263	ISSUED	VICAL.01E
Lipid Derivatives of Antiviral Nucleosides, Liposomal Incorporation and Method of Use	PCT/US89/02909	WO 90/00555	PUBLISHED	VESTAR.P01
Lipid Derivatives of Antiviral Nucleosides, Liposomal Incorporation and Method of Use	AUSTRALIA 39676/89	AUSTRALIA 620901	ISSUED	V.001VAU

TITLE	APPLICATION NO.	PATENT NO.	STATUS	REFERENCE NO.
Lipid Derivatives of Antiviral Nucleosides, Liposomal Incorporation and Method of Use	CANADA 604,898	CANADA 1,334,846	ISSUED	V.C01
Lipid Derivatives of Antiviral Nucleosides, Liposomal Incorporation and Method of Use	DENMARK 0012/91		PENDING	V.001VDK
Lipid Derivatives of Antiviral Nucleosides, Liposomal Incorporation and Method of Use	EUROPE 89306815.5		PENDING	V.U01
Lipid Derivatives of Antiviral Nucleosides, Liposomal Incorporation and Method of Use	FINLAND 910031		ABANDONED	V.001VF1
Lipid Derivatives of Antiviral Nucleosides, Liposomal Incorporation and Method of Use	HUNGARY 4392/89		ABANDONED	V.001VHU
Lipid Derivatives of Antiviral Nucleosides, Liposomal Incorporation and Method of Use	IRELAND 2187/89		PENDING	V.011
Lipid Derivatives of Antiviral Nucleosides, Liposomal Incorporation and Method of Use	ISRAEL 90848		ABANDONED	V.X01

TITLE	APPLICATION NO.	PATENT NO.	STATUS	REFERENCE NO.
Lipid Derivatives of Antiviral Nucleosides, Liposomal Incorporation and Method of Use	JAPAN 508037/1989		ABANDONED	V.001VJP
Lipid Derivatives of Antiviral Nucleosides, Liposomal Incorporation and Method of Use	KOREA 700490/1990		ABANDONED	V.001VKR
Lipid Derivatives of Antiviral Nucleosides, Liposomal Incorporation and Method of Use	NEW ZEALAND 229844	NEW ZEALAND 229844	ISSUED	V.Z01
Lipid Derivatives of Antiviral Nucleosides, Liposomal Incorporation and Method of Use	MALAYASIA PI8900911		ABANDONED	V.0M1
Lipid Derivatives of Antiviral Nucleosides, Liposomal Incorporation and Method of Use	PAKISTAN 265/89	131839	ABANDONED	V.0Z1
Lipid Derivatives of Antiviral Nucleosides, Liposomal Incorporation and Method of Use	PHILIPPINES 38914		ABANDONED	V.0P1
Lipid Derivatives of Antiviral Nucleosides, Liposomal Incorporation and Method of Use	PORTUGUESE 91101	PORTUGUESE 91101	ISSUED	V.0R1

TITLE	APPLICATION NO.	PATENT NO.	STATUS	REFERENCE NO.
Lipid Derivatives of Antiviral Nucleosides, Liposomal Incorporation and Method of Use	SOUTH AFRICA 89/5136		ABANDONED	V.0K1
Lipid Derivatives of Antiviral Nucleosides, Liposomal Incorporation and Method of Use	TAIWAN 78105415	53061	ABANDONED	V.Y01
Lipid Derivatives of Antiviral Nucleosides, Liposomal Incorporation and Method of Use	THAILAND 008963		ABANDONED	V.0T1
Lipid Derivatives of Antiviral Nucleosides: Liposomal Incorporation and Method of Use	08/040,499		ABANDONED	V.001C1
Lipid Derivatives of Antiviral Nucleosides: Liposomal Incorporation and Method of Use	08/415,769		PENDING	V.1C1FW1
Method of Treating Viral Infections Using Antiviral Liponucleotides	08/483,148		PENDING	V.1CFDV1
HEPATITIS APPLICATIONS/PATENTS				
Antiviral Liponucleosides: Treatment of Hepatitis B	07/730,273		ABANDONED	V.1CP3
Antiviral Liponucleosides: Treatment of Hepatitis B	PCT/US92/04856	WO 93/00910	PUBLISHED	V.001BPC

TITLE	APPLICATION NO.	PATENT NO.	STATUS	REFERENCE NO.
Antiviral Liponucleosides: Treatment of Hepatitis B	AUSTRALIA 22268/92	AUSTRALIA 668873	ISSUED	V.001BAU
Antiviral Liponucleosides: Treatment of Hepatitis B	CANADA 2112803		PENDING	V.001BCA
Antiviral Liponucleosides: Treatment of Hepatitis B	EUROPE 92914562.1		ABANDONED	V.001BEP
Antiviral Liponucleosides: Treatment of Hepatitis B	JAPAN 502213/1993		PENDING	V.001BJP
Antiviral Liponucleosides: Treatment of Hepatitis B	08/222,571		ALLOWED	V.1CP3FWC
Antiviral Liponucleosides: Treatment of Hepatitis B	08/456,537	5,817,638	ISSUED	V.1CP3FD1
PHOSPHONOFORMATE APPLICATIONS/PATENTS				
Lipid Derivatives of Phosphonoacids for Liposomal Incorporation and Method of Use	07/440,898	5,194,654	ISSUED	V.007A
Lipid Derivatives of Phosphonoacids for Liposomal Incorporation and Method of Use	07/993,133	5,463,092	ISSUED	V.007CP1
Lipid Derivatives of Phosphonoacids for Liposomal Incorporation and Method of Use	PCT/US92/10991	WO 94/13682	PUBLISHED	V.007QPC

TITLE	APPLICATION NO.	PATENT NO.	STATUS	REFERENCE NO.
Lipid Derivatives of Phosphonoacids for Liposomal Incorporation and Method of Use	AUSTRALIA 33287/93	AUSTRALIA 680812	ISSUED	V.007QAU
Lipid Derivatives of Phosphonoacids for Liposomal Incorporation and Method of Use	CANADA 2149753		PENDING	V.007QCA
Lipid Derivatives of Phosphonoacids for Liposomal Incorporation and Method of Use	EUROPE 93901148.2		PENDING	V.007QEP
Lipid Derivatives of Phosphonoacids for Liposomal Incorporation and Method of Use	JAPAN 514102/94		PENDING	V.007QJP
Lipid Derivatives of Phosphonoacids for Liposomal Incorporation and Method of Use	08/451,221	5,744,461	ISSUED	V.007CPDV1
ORAL (BATYL) APPLICATIONS/PATENTS				
Method of Converting a Drug to an Orally Available Form by Covalently Bonding a Lipid to a Drug	07/991,166	5,411,947	ISSUED	V.10A
Lipid Prodrugs for Oral Administration	PCT/US93/12241	WO 94/13324	PUBLISHED	V.010VPC
Lipid Prodrugs for Oral Administration	AUSTRALIA 58031/94	681619	ABANDONED	V.10VAU
Lipid Prodrugs for Oral Administration	CANADA 2149754		ABANDONED	V.10VCA
Lipid Prodrugs for Oral Administration	EUROPE 94903663.6		ABANDONED	V.10VEP

TITLE	APPLICATION NO.	PATENT NO.	STATUS	REFERENCE NO.
Lipid Prodrugs for Oral Administration	JAPAN 514518/94		PENDING	V.10VJP
Prodrugs for Oral Administration Containing Taxol or Substituted Taxol Covalently Bound to a Phospholipid	08/355,510	5,484,809	ISSUED	V.10DV1
Lipid Prodrugs for Oral Administration: Method of Making	08/482,431	5,744,592	ISSUED	V.10DVC1
Lipid Prodrugs for Oral Administration	08/484,018	5,827,831	ISSUED	V.10DVC2
UTRECHT APPLICATIONS/PATENTS				
Synthesis of Diacyl or Diradyl Glycerol Di- and Triphosphate Derivatives	07/530,556		ABANDONED	V.17A
Synthesis of Glycerol Di- and Triphosphate Derivatives	07/706,873		ABANDONED	V.17CP1
Synthesis of Glycerol Di- and Triphosphate Derivatives	PCT/US91/03736	WO 91/18914	PUBLISHED	V.17QPC
Synthesis of Glycerol Di- and Triphosphate Derivatives	AUSTRALIA 81845/91	647164	ABANDONED	V.17QAU
Synthesis of Glycerol Di- and Triphosphate Derivatives	CANADA 2083961-9		ABANDONED	V.17QCA
Synthesis of Glycerol Di- and Triphosphate Derivatives	EUROPE 91912531.0		ABANDONED	V.17QEP

TITLE	APPLICATION NO.	PATENT NO.	STATUS	REFERENCE NO.
Synthesis of Glycerol Di- and Triphosphate Derivatives	JAPAN 511730/91		ABANDONED	V.17QJP
Synthesis of Glycerol Di- and Triphosphate Derivatives	08/251,018	5,780,617	ISSUED	V.17CFW1
PROTEASE INHIBITOR APPLICATIONS/PATENTS				
Lipid Peptide Conjugates of Therapeutic Peptides and Protease Inhibitors	07/734,434	5,554,728	ISSUED	V.019A
Lipid Peptide Conjugates of Therapeutic Peptides and Protease Inhibitors	08/458,401	5,804,552	ISSUED	V.019DV1
Lipid Conjugates of Therapeutic Peptides and Protease Inhibitors	PCT/US92/06153	WO 93/01828	PUBLISHED	V.019VPC
Lipid Conjugates of Therapeutic Peptides and Protease Inhibitors	AUSTRALIA 24251/92	671078	ABANDONED	V.019VAU
Lipid Conjugates of Therapeutic Peptides and Protease Inhibitors	CANADA 2113156		ABANDONED	V.019VCA
Lipid Conjugates of Therapeutic Peptides and Protease Inhibitors	EUROPE 92917096.7		ABANDONED	V.019VEP
Lipid Conjugates of Therapeutic Peptides and Protease Inhibitors	JAPAN 503064/1993		ABANDONED	V.019VJP

L:\WPDOCS\Prodrug\appendixa.wpd /mah

ATTESTATION

I, Mary Ann Holland, hereby certify that I made the attached photocopy of an assignment from NEXSTAR PHARMACEUTICALS, INC. executed by MARK L. PERRY, Vice President and Chief Financial Officer of NEXSTAR PHARMACEUTICALS, INC., as assignor to KARL Y. HOSTETLER, as assignee, from the original copy of said assignment and that the attached photocopy is true copy of the original.



Mary Ann Holland

STATE OF COLORADO)
) ss.
COUNTY OF DOUGLAS)


This attestation was acknowledged before me this 18th day of May, 2000, by **MARY ANN HOLLAND**.

Witness my hand and official seal.

My Commission Expires: _____

By: _____

Notary Public



My Commission Expires March 29, 2002

\\Swansonbrats01\mah\WPDOCS\Prodrug\assign attestation.wpd /mah